21P Progression-free survival and overall survival with pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer following progression with EGFR TKI in China: Phase II study results

Pumitamig (BNT327/BMS986545) is an investigational bispecific antibody designed to target both PD-L1 and VEGF-A in the tumor and tumor microenvironment that has shown encouraging antitumor activity in combination with chemo in pts with previously treated EGFR-mutated NSCLC. Here, we present PFS and OS data from an ongoing single-arm phase II study of pumitamig + chemo in pts with EGFR-mutated advanced NSCLC who progressed on or after standard EGFR TKI treatment.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-03-17
DOI
https://doi.org/10.1016/j.esmoop.2026.106328
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

21P Progression-free survival and overall survival with pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer following progression with EGFR TKI in China: Phase II study results

Ping Duan, Tingting Zhou, Y. Wu, Z. Wang et al.
ESMO Open
Cancer Immunotherapy and Biomarkers
article

21P Progression-free survival and overall survival with pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer following progression with EGFR TKI in China: Phase II study results

Ping Duan, Tingting Zhou, Y. Wu, Z. Wang, T. Zhang, C. Hu, J. Fang, Y. Wang, S. He, D. Lv, H. Zhao, H. Su, Y. Pan, P. Zhang, X. Meng, Y. Du, W. Zuo, M. Sun, Y. Zhao, H. Liu
article en

Abstract

Pumitamig (BNT327/BMS986545) is an investigational bispecific antibody designed to target both PD-L1 and VEGF-A in the tumor and tumor microenvironment that has shown encouraging antitumor activity in combination with chemo in pts with previously treated EGFR-mutated NSCLC. Here, we present PFS and OS data from an ongoing single-arm phase II study of pumitamig + chemo in pts with EGFR-mutated advanced NSCLC who progressed on or after standard EGFR TKI treatment.

ESMO OpenVol. 11
Nanchang University (CN), Harbin Medical University (CN), Anhui Medical University (CN), Peking University (CN), Wenzhou Medical University (CN), Zhengzhou University (CN), Peking University Cancer Hospital (CN), Jilin Province Tumor Hospital (CN), Beijing Biocytogen (China) (CN), Shandong Tumor Hospital (CN), Integrated Chinese Medicine (China) (HK), Third Affiliated Hospital of Harbin Medical University (CN), Jinan Central Hospital (CN), Shanghai Pulmonary Hospital (CN), Anhui Provincial Hospital (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), First Affiliated Hospital of Anhui Medical University (CN), Henan Cancer Hospital (CN), Shanghai Sixth People's Hospital (CN), Changzhou No.2 People's Hospital (CN), Guangdong Provincial People's Hospital (CN), Tang Du Hospital (CN), Zhejiang Taizhou Hospital (CN), Shandong First Medical University (CN), First Affiliated Hospital of Nanchang University (CN), Chengdu University of Traditional Chinese Medicine (CN), Chongqing Medical University (CN)
Good health and well-being
Openalex Percentile: Top 20%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.